logo-loader
viewShield Therapeutics PLC

Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru.

The drug's approved and marketed in Europe, with a US approval decision pending for July 27.

Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable to tolerate or unresponsive to first-line salt-based oral iron products.

Quick facts: Shield Therapeutics PLC

Price: 98 GBX

LSE:STX
Market: LSE
Market Cap: £114.84 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics CEO says all efforts are on securing US partner for Feraccru

Shield Therapeutics PLC’s (LON:STX) chief executive Tim Watts caught up with Proactive's Andrew Scott on the back of its 2019 results. He says that finding a US partner for its iron deficiency drug Accrufer is the top priority for 2020. Shield already has commercial agreements in Europe...

4 days, 10 hours ago

2 min read